Clinical Trials on Acute Lymphocytic Leukaemia Refractory

Total 5865 results

Sumithira Vasu

Recruiting

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent High Grade... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | T-Cell Large Granular Lymphocyte Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage...

United States, Denmark, Italy
Sanofi

Recruiting

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Myelodysplastic Syndromes | Acute Lymphocytic Leukaemia | Acute Myeloid Leukaemia Refractory | Blastic Plasmacytoid Dendritic Cell Neoplasia

Netherlands, France, United States, Australia, China
Hospital Israelita Albert Einstein
Miltenyi Biotec, Inc.

Not yet recruiting

A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies (CARTHIAE-1)

Acute Lymphoblastic Leukemia, in Relapse | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Chronic Lymphocytic Leukemia Recurrent | Chronic Lymphocytic Leukemia Refractory | Acute Lymphoblastic Leukemia Refractory

Brazil
Syndax Pharmaceuticals

Active, not recruiting

A Study of SNDX-5613 in Combination With Chemotherapy in Participants With R/R Acute Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Undifferentiated Leukemia | Relapsed/Refractory Leukemias | Mixed Phenotype Acute Leukemia

United States, Canada
M.D. Anderson Cancer Center
Ziopharm Oncology

Terminated

CD19-Specific T Cells Post AlloSCT

Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory B Acute Lymphoblastic Leukemia | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory... and other conditions

United States
M.D. Anderson Cancer Center

Not yet recruiting

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

B-cell Acute Lymphocytic Leukemia | Relapsed/Refractory

United States
First Affiliated Hospital of Wenzhou Medical University
Second Affiliated Hospital of Nanchang University; Hrain Biotechnology Co.,...

Unknown

Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma

Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | B-cell Adult Acute Lymphoblastic Leukemia

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

Recurrent Mantle Cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin... and other conditions

United States
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia

Relapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory Non-Hodgkin Lymphoma | Relapsed or Refractory Chronic Lymphocytic Leukemia

United Kingdom, Spain, France, Australia
AstraZeneca
CLL Consortium

Completed

AZD6738 First Time in Patient Multiple Ascending Dose Study

B Cell Lymphomas | 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), | Prolymphocytic Leukaemia (PLL)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Progressive Disease | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Minimal Residual Disease | Recurrent Chronic Lymphocytic Leukemia | CD19 Positive | CD22...

United States
Xijing Hospital
Xi'An Yufan Biotechnology Co.,Ltd

Recruiting

CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.

Lymphoma, B-Cell | CD19 Positive | Leukemia Lymphocytic Acute (ALL) in Relapse | Leukemia Lymphocytic Acute (All) Refractory

China
Sanofi

Terminated

SAR3419 in Acute Lymphoblastic Leukemia (MYRALL)

Acute Lymphocytic Leukaemia

United States, France
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Intra-Osseous Co-Transplant of UCB and hMSC

Myelodysplastic Syndromes | Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Myelofibrosis | Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Refractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Lymphoid Malignancies | Relapsed Non-Hodgkin Lymphoma and other conditions

United States
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

Study of APG2575 Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Myeloid Malignancy | Relapsed/Refractory Acute Myeloid Leukaemia

China
Miltenyi Biomedicine GmbH

Recruiting

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Acute Lymphoblastic Leukemia Recurrent | Chronic Lymphocytic Leukemia Recurrent | Chronic Lymphocytic Leukemia Refractory

Germany
National Cancer Institute (NCI)

Completed

XK469R in Treating Patients With Refractory Hematologic Cancer

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia... and other conditions

United States
Beth Israel Deaconess Medical Center
Genzyme, a Sanofi Company

Completed

Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Acute Lymphocytic Leukemia | Hodgkins Disease | Relapsed/Refractory Chronic Lymphocytic Leukemia | Relapsed Refractory Multiple Myeloma | Relapsed/Refractory Non Hodgkin's Lymphoma

United States
Virginia Commonwealth University
Gilead Sciences

Withdrawn

Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL (RIVe-CLL/SLL)

Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | Refractory Small Lymphocytic Lymphoma | SLL | Relapsed CLL | Relapsed Chronic Lymphocytic Leukemia | Relapsed Small Lymphocytic Lymphoma
BeiGene

Completed

Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Relapsed or Refractory Chronic Lymphocytic Leukemia | Relapsed or Refractory Small Lymphocytic Lymphoma

China
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)

Completed

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Recurrent B-Cell Prolymphocytic Leukemia | Refractory B-Cell Prolymphocytic Leukemia

United States
Emory University
Novartis

Terminated

Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)

Completed

Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia

T-cell Large Granular Lymphocyte Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Recurrent Transformed Chronic Lymphocytic Leukemia | Refractory...

United States
National Cancer Institute (NCI)

Terminated

Sunitinib in Treating Patients With Idiopathic Myelofibrosis

Primary Myelofibrosis | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia... and other conditions

United States
Fred Hutchinson Cancer Center
AstraZeneca

Recruiting

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Kite, A Gilead Company

Terminated

Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ZUMA-8)

Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma

United States, Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Unknown

NK Cells in Cord Blood Transplantation

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia and other conditions

United States
University Hospital Tuebingen

Recruiting

Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia (Anti-CD19-ALL)

ALL, Childhood B-Cell | Acute Lymphoid Leukemia Relapse | Acute Lymphocytic Leukemia Refractory

Germany
University of California, Irvine
United States Department of Defense

Active, not recruiting

Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Chronic Lymphocytic Leukemia | AML, Adult | CLL | CLL, Relapsed | CLL, Refractory

United States
Beijing GoBroad Hospital

Recruiting

Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia

Refractory/Relapsed Acute Myeloid Leukaemia

China
Eastern Cooperative Oncology Group

Completed

Phase III rhu_GM-CSF + 3 Induction Regimens in Adults With Acute Non-Lymphocytic Leukemia

Adult Patients (Over 55) With Acute Non-Lymphocytic Leukemia
M.D. Anderson Cancer Center

Active, not recruiting

Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Steven E. Coutre

Completed

Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

Refractory Hodgkin Lymphoma | Recurrent Adult Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | T-Cell Chronic Lymphocytic Leukemia | Recurrent Childhood Non-Hodgkin... and other conditions

United States, Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor

Refractory Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Masonic Cancer Center, University of Minnesota

Completed

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma | Non-Hodgkin's Lymphoma | Myelofibrosis | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | MDS | Chronic Myelogenous Leukemia | Prolymphocytic Leukemia | Refractory Anemia

United States
National University of Malaysia
Gaia Science

Recruiting

Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL

Relapsed B Acute Lymphoblastic Leukaemia | Refractory B Acute Lymphoblastic Leukaemia

Malaysia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
M.D. Anderson Cancer Center

Active, not recruiting

Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Richter Syndrome | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
University Health Network, Toronto
Takara Bio Inc.

Recruiting

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Relapsed or Refractory Chronic Lymphocytic Leukemia | Relapsed or Refractory Small Lymphocytic Lymphoma | Relapsed or Refractory CD19+ B-cell Lymphoma

Canada
Stanford University

Terminated

Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)

Leukemia | Leukemia, Lymphocytic, Acute | Leukemia Acute Promyelocytic Leukemia (APL) | Leukemia Acute Lymphoid Leukemia (ALL) | Leukemia Chronic Myelogenous Leukemia (CML) | Leukemia Acute Myeloid Leukemia (AML) | Leukemia Chronic Lymphocytic Leukemia (CLL)

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia

United States
Allogene Therapeutics

Recruiting

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) (ALPHA2)

Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

United States, Spain, Canada, Australia, Italy

Clinical Trials on Acute Lymphocytic Leukaemia Refractory

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations